CLB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetMaterial deleveraging and steady equity growth strengthen Core Laboratories’ resilience through industry cycles. A more conservative balance sheet can support ongoing customer commitments, preserve financing flexibility, and reduce pressure on cash flows while the company pursues recovery and growth.
Positive Cash GenerationConsistently positive free cash flow provides internally generated funding for capital investment, dividends, and other shareholder returns. Although conversion varies, the recurring cash-generation base gives Core Laboratories greater durability than a business dependent solely on external financing.
Technology CommercializationRegulatory approval and expanding deployment of proprietary technologies can deepen Core Laboratories’ role in reservoir optimization and production decisions. Broader adoption, combined with new international characterization engagements, supports differentiated services and potentially more durable customer relationships.
Bears Say
Revenue And Earnings DownturnThe recent top-line and earnings decline indicates that operating performance has not yet returned to a durable growth trajectory. Continued softness could limit margin expansion, reduce reinvestment capacity, and make results more dependent on an eventual recovery in customer activity.
Reservoir Description WeaknessReservoir Description is a core service line, so its lower revenue and compressed margin weigh materially on the company’s earnings mix. Persistent weakness would reduce the benefit of its technical capabilities and could offset improvement in Production Enhancement over coming quarters.
Geopolitical And Operational DisruptionOngoing regional conflicts are disrupting project execution and logistics across affected markets, while Core Laboratories continues carrying associated costs. These conditions can delay service revenue, pressure utilization and margins, and prolong recovery in internationally exposed operations.
Core Laboratories News
CLB FAQ
What was Core Laboratories N.V.’s price range in the past 12 months?
Currently, no data Available
What is Core Laboratories N.V.’s market cap?
Core Laboratories N.V.’s market cap is $9.67B.
When is Core Laboratories N.V.’s upcoming earnings report date?
Core Laboratories N.V.’s upcoming earnings report date is Oct 28, 2026 which is in 47 days.
How were Core Laboratories N.V.’s earnings last quarter?
Core Laboratories N.V. released its earnings results on Jul 29, 2026. The company reported $1.865 earnings per share for the quarter, beating the consensus estimate of $1.475 by $0.39.
Is Core Laboratories N.V. overvalued?
According to Wall Street analysts Core Laboratories N.V.’s price is currently Undervalued.
Does Core Laboratories N.V. pay dividends?
Core Laboratories N.V. does not currently pay dividends.
What is Core Laboratories N.V.’s EPS estimate?
Core Laboratories N.V.’s EPS estimate is 2.61.
How many shares outstanding does Core Laboratories N.V. have?
Core Laboratories N.V. has 45,884,540 shares outstanding.
What happened to Core Laboratories N.V.’s price movement after its last earnings report?
Core Laboratories N.V. reported an EPS of $1.865 in its last earnings report, beating expectations of $1.475. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Core Laboratories N.V.?
Currently, no hedge funds are holding shares in MX:CLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Core Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$186.74 (― Upside)
$186.74 (― Upside)
Blogger Sentiment
Bullish
MX:CLB Sentiment 75%
Sector Average 58%
Sector Average 58%
Insider Transactions
Bought Shares
Worth $910.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Core Laboratories N.V.
Core Laboratories N.V. (CLB) is a global provider to the oil and gas sector, delivering specialized services and products for characterizing subterranean reservoirs and optimizing hydrocarbon extraction. The company's operations are distinctly segmented into Reservoir Description and Production Enhancement. The Reservoir Description division meticulously analyzes petroleum reservoir rock, fluid, and gas samples. This detailed scientific examination aims to boost the yield and enhance the recovery of oil and gas from clients' reservoirs. Offerings in this segment encompass comprehensive laboratory analysis and on-site field evaluations to determine the properties of crude oil and refined products, alongside performing proprietary and collaborative industry research studies. Conversely, the Production Enhancement segment furnishes an array of services and products vital for well completions, perforations, stimulation processes, and general production activities. This includes providing integrated diagnostic tools designed to assess the efficacy of well completions and to devise strategies for more effective enhanced oil recovery initiatives. Core Laboratories markets and sells its solutions through diverse channels, including direct sales representatives, educational seminars, industry trade exhibitions, print advertising, and a network of distributors. Established in 1936, the company boasts a significant international presence, conducting operations in approximately 50 countries, with its corporate headquarters situated in Amstelveen, the Netherlands.
CLB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted clear sequential improvements in revenue, margins, product sales, and operating profitability, a constructive Q3 outlook, continued technology commercialization and disciplined capital returns. However, year-over-year revenue and earnings declined, with significant near-term headwinds from geopolitical conflicts (Middle East and Russia/Ukraine) adversely affecting assay and service work and forcing ongoing cost carry and regional operating challenges. Management emphasizes operational resilience, technology adoption, and shareholder returns while guiding for sequential growth into Q3.View all MX:CLB earnings summaries